CXCR4 and neoplasm: Based on this literature, another group explored the use of the T22-PE24-H6 nanotoxin to induce tumor-selective and gasdermin-mediated immunogenic cell death in CXCR4+ melanoma mouse models, achieving strong synergy when combined with an anti-PD-1 immune checkpoint inhibitor therapy [263].